This Week in Managed Care: July 31, 2020
July 31st 2020This week, the top managed care news included top pharmaceutical executives refuse to attend a Trump meeting after executive orders on costs; a survey shows concerns about reopening schools, toll of COVID-19 split by party lines, background; a review of 20 years of data concludes vaccines are "remarkably safe."
What We're Reading: Prevalence of Underlying Conditions; Opioid Label Change; ICE Detainees Held
July 24th 2020New CDC data outline the prevalence of 5 common underlying health conditions that exacerbate coronavirus disease 2019 (COVID-19) symptoms; the FDA announced information regarding naloxone must be included on labels for opioids and opioid use disorder medications; despite a district judge's ruling nearly a month ago, hundreds of migrant detainees are being held in detention centers in states where COVID-19 cases are surging.
Ruxolitinib Improves ORR Over Best Available Therapy in Patients With Chronic GVHD
July 24th 2020A phase 3 study of ruxolitinib (Jakafi) has met its primary end point of superior overall response rate (ORR) compared with the best available therapy in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD).
National Kidney Foundation, NCQA Announce Measure to Boost Testing in Patients With Diabetes
July 24th 2020While clinical guidelines call for those with diabetes to be tested regularly for kidney disease, less than 50% of these patients are tested once a year, according to the National Kidney Foundation.